NASDAQ:PHVS Pharvaris Q3 2026 Earnings Date & Estimates $33.64 -0.55 (-1.59%) As of 10:09 AM Eastern This is a fair market value price provided by Massive. Learn more. Pharvaris is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 12, 2026TimeBefore Market Opens Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Pharvaris in Q3 2026Pharvaris is expected to post earnings of -$0.8187 per share on revenue of $2.35 million. In the same quarter a year earlier Pharvaris reported -$0.70 per share. Pharvaris last reported on August 12, 2026, posting -$0.81 per share and missing the -$0.7467 consensus estimate. Pharvaris has beaten the consensus EPS estimate in 3 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.8187Expected Revenue$2.35 millionPrior-Year EPS-$0.70Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.81 (Missed by -$0.0633)EPS Beat Rate3 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Pharvaris Q3 2026 Earnings FAQ When does Pharvaris report Q3 2026 earnings? Pharvaris (NASDAQ:PHVS) is estimated to report Q3 2026 earnings on Thursday, November 12, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Pharvaris' Q3 2026 earnings call? Pharvaris' Q3 2026 earnings conference call is scheduled for Thursday, November 19, 2026 at 12:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Pharvaris? Analysts expect Pharvaris to post earnings of -$0.8187 per share for Q3 2026. How much revenue is Pharvaris expected to report? The consensus revenue estimate for Pharvaris is $2.35 million for Q3 2026. Pharvaris Earnings HeadlinesPharvaris Q3 2026: Wider Loss as FDA Decision Nears1 hour ago | 247wallst.comPharvaris Reports Third Quarter 2026 Financial Results and Provides Business Update3 hours ago | globenewswire.comSocial Security’s trust fund runs short in 2032. Guess who controls Congress.Social Security's retirement trust fund is projected to run dry in late 2032, per the 2026 Trustees Report. After that, only about 78% of scheduled benefits can be paid unless Congress acts. Higher taxes, smaller checks or more borrowing are all on the table. The morning after Democrats took Congress, gold jumped almost 3% and silver jumped 4%. If you count on Social Security for any part of your retirement, a backup plan matters before 2032.November 12 at 1:00 AM | Priority Gold (Ad)Analysts’ Opinions Are Mixed on These Healthcare Stocks: Immunocore Holdings (IMCR), Pharvaris (PHVS) and Moderna (MRNA)November 10 at 2:49 PM | theglobeandmail.comPharvaris (PHVS) Expected to Post Quarterly Earnings on WednesdayNovember 10 at 3:11 AM | americanbankingnews.comPharvaris (PHVS) Stock Could Look Pricey Following Phase 3 MomentumNovember 4, 2026 | finance.yahoo.comSee More Pharvaris Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email. Email Address About PharvarisPharvaris (NASDAQ:PHVS) is a clinical-stage biopharmaceutical company focused on developing oral treatments for hereditary angioedema (HAE) and other conditions involving bradykinin-mediated swelling. The company was founded in 2015 and is based in Leiden, the Netherlands. Its lead candidate, deucrictibant, is an oral small-molecule antagonist of the bradykinin B2 receptor. Pharvaris is studying the candidate in different formulations for both on-demand treatment of HAE attacks and prevention of attacks. Pharvaris does not have a marketed product; its work centers on research and clinical development. Its programs are intended to offer an oral alternative to existing HAE treatments, many of which are administered by injection.View Pharvaris ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Keeping AI Cool: AAON Rides the AI Heatwave to Record GrowthPalantir’s Real Washington Risk Isn’t the Budget—It’s OversightCan Constellation Energy's Contracts Power a Stock Rebound?IonQ Raised the Bar, But 3 Quantum Rivals Face Tough QuestionsAmazon's Rally Is Outpacing Big Tech, But Can AWS Justify the AI Spending?Aehr Test Systems Notches Another Post-Earnings Win as Sales Triple on AI DemandAST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn't Going Away Upcoming Earnings Mizuho Financial Group (11/13/2026)Mitsubishi UFJ Financial Group (11/13/2026)Sumitomo Mitsui Financial Group (11/13/2026)Home Depot (11/17/2026)Walt Disney (11/17/2026)NVIDIA (11/17/2026)Lowe's Companies (11/18/2026)PDD (11/18/2026)TJX Companies (11/18/2026)Target (11/18/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
